Pure Global
NCT04566445

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
Gyroscope Therapeutics Limited·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
GT005: Medium Dose
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Gyroscope Therapeutics Limited
Location
Phoenix,Beverly Hills,Fullerton,Palo Alto,Poway,Durango,Deerfield Beach,Gainesville,Miami,Saint Petersburg,Augusta,Marietta,Oak Forest,Indianapolis,West Des Moines,Lenexa,Baltimore,Boston,Grand Blanc,, Australia,France,Germany,Spain,United Kingdom,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Nov 11, 2020
End date
Oct 31, 2023
Enrollment
180 participants
Primary outcome

Progression of geographic atrophy

Summary

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of
 GT005 administered as a single subretinal injection in subjects with geographic atrophy
 secondary to age-related macular degeneration (AMD).

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04566445
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04566445 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gyroscope Therapeutics Limited and is currently Recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.